Physician profile
Christopher Lamotte
NPI 1275812349
$3,084.73
in general payments reported to CMS, 2019-2025
18 companies · $862 in 2025
The $862 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $778 · 2022: $241 · 2023: $485 · 2024: $719 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,065.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $857.72 | 2021-2025 | Camzyos, Eliquis |
| Biotronik INC. | $753.13 | 2021-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Astrazeneca Pharmaceuticals LP | $286.99 | 2021-2025 | Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $178.45 | 2022-2023 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $150.97 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $143.41 | 2025 | Wegovy |
| Inari Medical, INC. | $124.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $100.45 | 2024 | Xarelto |
| Abiomed | $96.51 | 2025 | |
| Pfizer INC. | $93.38 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $80.68 | 2021-2025 | |
| Amgen INC. | $68.50 | 2021-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.91 | 2024 | Jardiance |
| Endologix LLC | $28.14 | 2024 | Torus Stent Graft System |
| Medtronic, INC. | $28.04 | 2025 | Azure Xt Dr Mri Surescan |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $27.14 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.84 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lamotte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.